Genelux Raises $18.5M, Holds $33.1M Cash with Phase 3 Readout in 2H26
Genelux entered 2026 with $33.1 million in pro forma cash at December 31, 2025, extending runway into 1Q27 after a $18.5 million January equity raise. The company expects Phase 3 ovarian cancer topline data in 2H26 and reported interim partial responses in lung cancer with Olvi-Vec.
1. Financial Position
Genelux reported $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash at December 31, 2025, including $18.5 million net proceeds from a January equity offering. Management expects these funds to support operations into the first quarter of 2027.
2. Phase 3 Ovarian Cancer Trial
The Phase 3 OnPrime/GOG-3076 registrational trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer is enrolling across US sites, with topline efficacy and safety data anticipated in the second half of 2026. The study compares Olvi-Vec plus platinum-doublet chemotherapy and bevacizumab against physician’s choice chemotherapy plus bevacizumab.
3. Interim Lung Cancer Data
Interim systemic data in platinum-resistant small cell lung cancer showed partial responses in 33% of patients, including two high-dose cohorts with tumor shrinkage of ~55% and ~85%. In non-small cell lung cancer, Olvi-Vec achieved a 60% disease control rate with tumor size reductions up to 22.7%.
4. Leadership Update
Jason Litten, M.D., joined as Chief Medical Officer in January 2026 to oversee clinical development strategy. He brings over 20 years of experience leading Phase 1-4 trials across biologics, small molecules and cellular therapies in oncology.